Technical Analysis for DRRX - DURECT Corporation

Grade Last Price % Change Price Change
grade D 0.7456 -1.22% -0.01
DRRX closed up 1.32 percent on Monday, March 18, 2019, on 61 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical DRRX trend table...

Date Alert Name Type % Chg
Mar 18 20 DMA Resistance Bearish -1.22%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.22%
Mar 18 NR7 Range Contraction -1.22%
Mar 18 Inside Day Range Contraction -1.22%
Mar 15 Fell Below 20 DMA Bearish 0.08%
Mar 14 Bearish Engulfing Bearish -4.41%
Mar 14 Outside Day Range Expansion -4.41%
Mar 13 Pocket Pivot Bullish Swing Setup -9.07%
Mar 13 Up 3 Days in a Row Strength -9.07%
Mar 13 Up 4 Days in a Row Strength -9.07%

Older signals for DRRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
DURECT Corporation, a specialty pharmaceutical company, develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. It focuses on the development of products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, cardiovascular disease, and other chronic diseases. The company manufactures and sells ALZET osmotic pumps used in laboratory research; and a range of LACTEL standard and custom biodegradable polymers and excipients used as raw materials for the pharmaceutical and medical device clients. Its product pipeline includes REMOXY, an oral oxycodone gelatin capsule for chronic pain, which has received complete response letter from the U.S. Food and Drug Administration (FDA); POSIDUR, a Phase III clinical trial release formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR, a Phase II transdermal sufentanil patch intended to provide delivery of sufentanil. The company's products pipeline also comprises ORADUR-based opioids, including hydrocodone and hydromorphone for the treatment of pain, which are in Phase I clinical trial; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It is also involved in developing various biologics programs/research programs in other therapeutic categories. DURECT Corporation has strategic agreements with Hospira, Inc., Nycomed Danmark ApS; Pain Therapeutics, Inc.; Zogenix, Inc.; and Pfizer Inc. The company was founded in 1998 and is headquartered in Cupertino, California.
Pharmaceutical Pain Chemical Compounds Organic Compounds Schizophrenia Euphoriants Cardiovascular Disease Chronic Pain Central Nervous System Disorders Morphinans Opioids Attention Deficit Hyperactivity Disorder Ethers Phenols Chronic Diseases Fentanyl Drug Delivery Technology Oxymorphone Treatment Of Attention Deficit Hyperactivity Disorder Hydromorphone Sufentanil
Is DRRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.55
52 Week Low 0.46
Average Volume 384,451
200-Day Moving Average 1.0958
50-Day Moving Average 0.6783
20-Day Moving Average 0.7663
10-Day Moving Average 0.7491
Average True Range 0.0567
ADX 24.82
+DI 23.875
-DI 20.2193
Chandelier Exit (Long, 3 ATRs ) 0.7299
Chandelier Exit (Short, 3 ATRs ) 0.8202
Upper Bollinger Band 0.8459
Lower Bollinger Band 0.6867
Percent B (%b) 0.43
BandWidth 20.775153
MACD Line 0.0215
MACD Signal Line 0.0263
MACD Histogram -0.0048
Fundamentals Value
Market Cap 110.95 Million
Num Shares 147 Million
EPS -0.26
Price-to-Earnings (P/E) Ratio -2.90
Price-to-Sales 7.10
Price-to-Book 0.00
PEG Ratio -0.16
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.81
Resistance 3 (R3) 0.81 0.80 0.80
Resistance 2 (R2) 0.80 0.78 0.80 0.80
Resistance 1 (R1) 0.78 0.78 0.77 0.77 0.79
Pivot Point 0.76 0.76 0.76 0.76 0.76
Support 1 (S1) 0.74 0.75 0.74 0.74 0.72
Support 2 (S2) 0.73 0.74 0.73 0.71
Support 3 (S3) 0.71 0.73 0.71
Support 4 (S4) 0.70